Novartis introduced a new organizational structure and operating model to integrate its Pharmaceuticals and Oncology business units, and create two separate commercial organizations—Innovative Medicines U.S. and Innovative Medicines International. According to the company, savings of at least $1 billion by 2024 will result from these changes.   The two units will have full P&L responsibility across all therapeutic areas, marketing and sales, and market access for their respective mar...